CN106117337B - CTL recognition epitope peptide of specific tumor antigen SF and application thereof - Google Patents
CTL recognition epitope peptide of specific tumor antigen SF and application thereof Download PDFInfo
- Publication number
- CN106117337B CN106117337B CN201610483184.0A CN201610483184A CN106117337B CN 106117337 B CN106117337 B CN 106117337B CN 201610483184 A CN201610483184 A CN 201610483184A CN 106117337 B CN106117337 B CN 106117337B
- Authority
- CN
- China
- Prior art keywords
- specific
- tumor antigen
- cells
- ctl
- epitope peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a CTL (cytotoxic T lymphocyte) recognition epitope peptide of a specific tumor antigen SF, which is nonapeptide, and the amino acid sequence of the CTL recognition epitope peptide is Glu-Lys-Asn-Val-Asn-Gln-Ser-Leu-Leu. The invention also discloses application of the epitope peptide in preparing a tumor therapeutic polypeptide vaccine with SF expression. The invention also discloses a method for preparing corresponding DC cells and DC-CIK cells by using the epitope peptide. The invention also discloses application of the DC cell and the DC-CIK cell.
Description
Technical Field
The invention relates to the technical field of epitope peptides, in particular to a CTL recognition epitope peptide of a specific tumor antigen SF and application thereof, a preparation method and application of a tumor antigen SF specific DC cell, and a preparation method and application of a tumor antigen SF specific DC-CIK cell.
Background
SF is an iron binding protein and elevated ferritin is found in the following tumors: acute leukemia, Hodgkin's disease, lung cancer, colon cancer, liver cancer and prostate cancer. The detection of ferritin has diagnostic value on liver metastatic tumor, and 76% of liver metastasis patients have ferritin content higher than 400 μ g/L, and can be supplemented with ferritin measured value under the condition of low AFP measured value in liver cancer to improve diagnosis rate. Ferritin is also elevated in pigmentation, inflammation, and hepatitis. The cause of the increase may be due to necrosis, blocked erythropoiesis or increased synthesis in tumor tissue. With the development of medical immunology and molecular biology, adoptive cellular immunotherapy approaches have been developed. Adoptive cell immunization refers to a method of culturing autologous or allogeneic peripheral blood mononuclear cells in vitro, and infusing the cells back into a patient after the cells proliferate to a certain amount, so as to kill tumors. Adoptive immunity comprises CIK, DC-CIK and the like, and the DC-CIK shows better targeting property and specificity and has stronger tumor killing effect. With the intensive research on the tumor development mechanism and the further understanding of the human immune system, the curative effect of the immunotherapy of the tumor is continuously improved, so that the complete cure of the tumor by the cellular immunotherapy becomes possible. At present, the immune cell therapy approaches gradually move to the clinic, and bring new hopes to cancer patients.
SF proteins are elevated in tumor or inflammatory responses, but are poorly expressed in normal tissues, so SF is specific for the preparation of adoptive immunotherapy for tumors. The preparation of SF-derived anti-tumor CTL epitopes and the application of the epitopes in the preparation of specific DC-CIK have certain effects on SF high-expression tumor treatment such as liver cancer.
Disclosure of Invention
Based on the technical problems of the background art, the present invention aims to provide a CTL epitope-recognizing peptide of specific tumor antigen SF.
The invention also aims to provide application of the CTL recognition epitope peptide of the specific tumor antigen SF.
The invention also aims to provide a preparation method of the tumor antigen SF-specific DC cell.
The invention also aims to provide a preparation method of the tumor antigen SF-specific DC-CIK cell.
The invention also aims to provide application of the DC cell and the DC-CIK cell specific to the tumor antigen SF.
In order to achieve the purpose, the invention adopts the following technical scheme:
the CTL recognition epitope peptide of the specific tumor antigen SF provided by the invention is nonapeptide, and the amino acid sequence of the CTL recognition epitope peptide is as follows: Glu-Lys-Asn-Val-Asn-Gln-Ser-Leu-Leu.
The CTL epitope peptide of the specific tumor antigen SF is synthesized by a solid phase synthesis method. The basic flow is as follows: firstly, connecting an amino acid with an amino group protected by Fmoc group on Wang resin of an insoluble solid phase carrier, and then removing the protecting group of the amino group, wherein the first amino acid is connected to the solid phase carrier; secondly, activating the second amino group by a carboxyl condensing agent of amino acid protected by Fmoc group, and reacting the activated second amino acid carboxyl with the amino group of the first amino acid connected with the solid phase carrier to form a peptide bond, thus generating the dipeptide with the protecting group on the solid phase carrier. Repeating the above peptide bond formation reaction to make peptide chain grow from C end to N end until reaching the required peptide chain length, finally cutting to obtain target peptide, and purifying by HPLC to obtain purity higher than 90%.
The invention also provides application of the CTL recognition epitope peptide of the specific tumor antigen SF in preparing a tumor therapeutic polypeptide vaccine with SF expression.
Preferably, the CTL recognition epitope peptide of the specific tumor antigen SF is applied to preparation of a liver cancer therapeutic polypeptide vaccine, and particularly has killing power on non-small cell liver cancer cells HepG 2.
The invention also provides a preparation method of the tumor antigen SF specific DC cell, which is obtained by adding CTL recognition epitope peptide of the specific tumor antigen SF into the DC cell for culture.
The invention also provides application of the specific DC cell obtained by the preparation method of the tumor antigen SF specific DC cell in preparing a medicament for treating liver cancer.
The invention also provides a preparation method of the tumor antigen SF specific DC-CIK cell, which is obtained by adopting CTL recognition epitope peptide of the specific tumor antigen SF for induction.
The invention also provides application of the specific DC-CIK cell obtained by the preparation method of the tumor antigen SF specificity DC-CIK cell in preparing a medicine for treating liver cancer.
The invention skillfully utilizes SF as a tumor-associated antigen with stronger specificity, presents high expression in liver cancer, breast cancer and digestive tumor, and expresses in normal tissues in low or trace amount, thereby screening the epitope peptide of the tumor-associated antigen by adopting a method combining theory and experiment, the obtained epitope peptide is not reported in documents, providing a theoretical basis for developing tumor vaccines or tumor specific CTL cells based on the antigen SF, and laying a foundation for the construction of subsequent multivalent antigen peptide vaccines.
Drawings
FIG. 1 is a diagram showing mass spectrometry analysis of a CTL recognition epitope peptide of a specific tumor antigen SF according to the present invention.
FIG. 2 is a graph showing a comparison of INF-. gamma.secretion ability of specific CTL cells induced by P1, P2, and P3 … … P20 obtained in example 1 of the present invention.
FIG. 3 is a graph showing the comparative killing ability of specific CTL cells induced by P2, P4, P10 and P12 obtained in example 1 of the present invention against hepatoma cell HepG 2.
FIG. 4 is a diagram showing the statistical analysis of flow cytometry detection data of a specific CTL cell immune cell population prepared from a CTL recognition epitope peptide of a specific tumor antigen SF according to the present invention.
Detailed Description
The technical solution of the present invention will be described in detail below with reference to specific examples.
Example 1: synthetic epitope peptides
By adopting a method combining theory and practice, according to the primary structure of the antigen, an immunoinformatics method is comprehensively applied, SYFPEITHI, BIMAS, NetCTL, WAPP and EpiJen are comprehensively applied to carry out prediction analysis on the antigen CTL epitope of SF, and the polypeptide sequences before 20 grades are selected for test screening, wherein the polypeptide sequences are named as P1, P2 and P3 … … P20 at one time.
The basic flow is as follows: firstly, connecting an amino acid with an amino group protected by Fmoc group on Wang resin of an insoluble solid phase carrier, and then removing the protecting group of the amino group, wherein the first amino acid is connected to the solid phase carrier; secondly, activating the second amino group by a carboxyl condensing agent of amino acid protected by Fmoc group, and reacting the activated second amino acid carboxyl with the amino group of the first amino acid connected with the solid phase carrier to form a peptide bond, thus generating the dipeptide with the protecting group on the solid phase carrier. Repeating the peptide bond forming reaction to enable the peptide chain to grow from the C end to the N end until the required peptide chain length is reached, and finally cutting to obtain the target epitope peptide crude product. And (3) purifying the crude product of the target epitope peptide by HPLC to obtain the target epitope peptide refined peptide, wherein the purity of the target epitope peptide refined peptide is more than 90%, and the molecular weight of the target epitope peptide refined peptide is proved to accord with a theoretical value by mass spectrometry.
The CTL recognition epitope peptide of the specific tumor antigen SF provided by the invention is synthesized by adopting an Fmoc solid-phase synthesis method, the CTL recognition epitope peptide is nonapeptide with the number of P10, and the amino acid sequence is as follows: Glu-Lys-Asn-Val-Asn-Gln-Ser-Leu-Leu. Mass spectrometry of P10 was carried out, and the results are shown in FIG. 1, which confirmed that the molecular weight was 1044.15968g/mol, which is in line with the theoretical value.
Example 2: polypeptide function detection
The P10 and the rest 19 epitope peptides obtained above can be used for preparing tumor therapeutic polypeptide vaccine with SF expression.
1. The CTL recognition epitope peptide induces specific CTL cells and IFN-gamma secretion and carries out killing experiment detection on tumor target cells: extracting peripheral blood of a patient, carrying out density gradient centrifugal separation to obtain PBMCs, adding cell factors to culture DC cells and CTL cells, further adopting the DC cells to load SF epitope peptide of the invention, carrying out co-culture with CTL to stimulate specific CTL to amplify, and further adopting ELISA and LDH experiments to detect the secretion of INF-gamma of the specific CTL under the stimulation of specific antigen and the killing effect on liver cancer cells HepG2 in vitro.
The specific method comprises the following steps:
(I) and PBMC separation and induction:
1) centrifuging 50mL of anticoagulated peripheral blood at 2000rpm for 10 min;
2) the upper plasma was collected and frozen, and the remaining blood cells were diluted with PBS (pH 7.4);
3) adding the diluted blood cells to the liquid surface of the equal volume of the lymph separation liquid;
4) centrifuging at 20 deg.C for 20min, and closing the centrifuge to brake;
5) centrifuging, dividing into four layers, and sucking the white membrane layer (i.e. the second layer) with a suction nozzle glass dropper;
6) the white film layer taken out is washed twice by PBS;
7) the cells are treated at 2-5X 10
6The cells are inoculated into a 6-well plate in a volume of one milliliter (mL) mode, after 2 hours, nonadherent cells are recovered, and activated and cultured by using a culture plate pre-coated with anti-CD3IgG and anti-CD28 IgG;
8) adding GM-CSF and IL-4 into adherent cells, stimulating and culturing for 5 days to induce DC cells, and changing the fluid for half the third day;
9) on the 5 th day, DC cells were collected, 10. mu.g of the epitope peptide propeptide of interest obtained in example 1 was added to the DC cells, and after 1 hour, the DC cells were co-cultured with activated T cells, while IL2 and IL-15 were added;
10) after further culturing for 5 days, the antigen specific CTL cell is obtained to carry out cytokine secretion and killing experiment on the tumor cell.
(II) IFN-gamma cytokine secretion detection: human IFN-gamma Platinum ELISA (IFN-gamma ELISA detection kit, eBioscience) detects IFN-gamma secreted by CTL cells, and the steps are as follows:
1) removing cytokines from CTL cells, culturing for 24h, and inoculating the CTL cells into a 96-well plate;
2) adding polypeptide corresponding to stimulation into the cells, stimulating for 24h again, centrifuging to remove the cells, and collecting cell supernatant;
3) and (3) detecting the expression of IFN-gamma in the supernatant by adopting ELISA, and selecting CTL epitope peptide with more IFN-gamma secretion for carrying out killing experiment.
The results are shown in fig. 2, P10 and P2, P4 and P12 loaded DC cells can induce specific CTL cells well and secrete high amounts of IFN- γ.
(III) tumor cell killing experiment: cell killing ability was measured by Lactate Dehydrogenase (LDH) release Assay using a CytoTox96Non-Radioactive cytoxicity Assay (Cytotoxicity Assay kit, Promega). The method comprises the following steps:
1) setting up a detection culture plate (100 mu L/hole)
a. Experimental groups were set up: using the liver cancer cell HepG2 with SF positive expression as a target cell, adding the CTL cell with the characteristics according to the ratio of the effector cell to the target cell of 5:1, 10:1 and 20:1
b. Establishment of effector cell spontaneous Release group
c. Set up target cell spontaneous release group
d. Setting the maximum release group of target cells
e. Setting up a background control group
2) Cell lysis and supernatant harvest
a.37℃5％CO
2Co-culturing for 5h
b. Adding lysis solution into the group with maximum release of target cells, centrifuging all the wells at 250g/min after 45min, and collecting supernatant
3) LDH detection
a. Transfer 50. mu.L of supernatant to another 96-well plate
b. Add 50. mu.L of diluted substrate mixture to each well and incubate in the dark at room temperature for 30min
c. Add 50. mu.L of stop solution per well
d. Detection of the absorbance OD at 490nm
The cell killing rate calculation formula is as follows:
percent of destruction (%) [ (OD)
Experimental group-OD
Effector cell spontaneous release group-OD
Target cell spontaneous release group)/(OD
Maximum release group of target cells-OD
Target cell spontaneous release group)]×100％
FIG. 3 shows the results, which are a graph comparing the killing ability of specific CTL cells induced by P2, P4, P10 and P12 obtained in example 1 of the present invention to hepatoma cell HepG 2; as shown in FIG. 3, the CTL cells induced by P10 were found to have the best killing effect on human hepatoma cells HepG 2.
2. The percentage of each immune cell in the specific CTLs obtained by flow analysis is shown in fig. 4. As shown in FIG. 4, the immune cell population prepared from P10 of the present invention contains a large number of CTL cells and a certain proportion of NKT cells, i.e., the immune cell population has good immunocompetence and strong ability to kill specific tumor cells.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (7)
1. The CTL recognition epitope peptide of the specific tumor antigen SF is nonapeptide, and the amino acid sequence of the CTL recognition epitope peptide is Glu-Lys-Asn-Val-Asn-Gln-Ser-Leu-Leu.
2. Use of a CTL epitope-recognizing peptide of the specific tumor antigen SF according to claim 1 for preparing a tumor therapeutic polypeptide vaccine with SF expression.
3. The use of CTL epitope peptide of specific tumor antigen SF according to claim 1 for the preparation of a therapeutic polypeptide vaccine for liver cancer.
4. A method for producing DC cells specific to tumor antigen SF, which comprises adding a CTL recognition epitope peptide of specific tumor antigen SF according to claim 1 to DC cells and culturing.
5. The use of the specific DC cell obtained by the method for preparing a tumor antigen SF-specific DC cell according to claim 4 in the preparation of a medicament for treating liver cancer.
6. A method for producing DC-CIK cells specific to tumor antigen SF, characterized in that the cells are induced by the CTL epitope-recognizing peptide of specific tumor antigen SF according to claim 1.
7. The use of the specific DC-CIK cell obtained by the method for preparing a tumor antigen SF-specific DC-CIK cell according to claim 6 in the preparation of a medicament for treating liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610483184.0A CN106117337B (en) | 2016-06-24 | 2016-06-24 | CTL recognition epitope peptide of specific tumor antigen SF and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610483184.0A CN106117337B (en) | 2016-06-24 | 2016-06-24 | CTL recognition epitope peptide of specific tumor antigen SF and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106117337A CN106117337A (en) | 2016-11-16 |
| CN106117337B true CN106117337B (en) | 2020-02-11 |
Family
ID=57265739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610483184.0A Active CN106117337B (en) | 2016-06-24 | 2016-06-24 | CTL recognition epitope peptide of specific tumor antigen SF and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106117337B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111116728B (en) * | 2020-01-13 | 2021-04-27 | 郑州大学 | Tumor specific antigen CTL epitope peptide and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102171340A (en) * | 2008-08-01 | 2011-08-31 | 肿瘤疗法科学股份有限公司 | MELK epitope peptides and vaccines containing the same |
-
2016
- 2016-06-24 CN CN201610483184.0A patent/CN106117337B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102171340A (en) * | 2008-08-01 | 2011-08-31 | 肿瘤疗法科学股份有限公司 | MELK epitope peptides and vaccines containing the same |
Non-Patent Citations (1)
| Title |
|---|
| Chicken major histocompatibility complex class II molecules of the B19 haplotype present self and foreign peptides;J.A.Cumberbatch.et al;《nternational Society for Animal Genetics》;20061231;第37卷;393-396 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106117337A (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105473731B (en) | The separation of itself cancer antigen-specific CD8+ T cell and enrichment procedure | |
| US10139395B2 (en) | Method for activation of helper T cell and composition for use in the method | |
| CN104769104A (en) | Process of expanding t cells | |
| CN107530392A (en) | It is used to treat and the sensitization of the T cell of epitope mapping and amplification method in artificial lymph node in vitro | |
| CN113101363B (en) | Circular RNA vaccine and application thereof | |
| CN106117337B (en) | CTL recognition epitope peptide of specific tumor antigen SF and application thereof | |
| EP2270144B1 (en) | Partial peptide of survivin presented on mhc class ii molecule and use thereof | |
| CN108289910A (en) | Artificial lymph node is for treating and the sensitization and amplification of the T cell of epitope mapping in vitro | |
| JP5267969B2 (en) | Cancer vaccine | |
| CN106117334B (en) | CTL recognition epitope peptide of tumor antigen MAGE3 and application thereof | |
| CN109535241B (en) | DC-CIK (dendritic cell-cytokine induced killer) co-culture cell, preparation method thereof, sensitizing antigen and application | |
| CN106117338B (en) | HLA-A0201-restricted CTL epitope of cytokeratin 19 | |
| CN106117339A (en) | The CTL of a kind of specific tumor antigen NSE identifies epitope peptide and application thereof | |
| CN106565828B (en) | Polypeptide for inducing DC-CIK cells and application thereof in tumor cell treatment | |
| CN105949303B (en) | CTL (cytotoxic T lymphocyte) recognition epitope peptide of specific tumor antigen CEA (CEA) and application thereof | |
| CN106008692A (en) | CTL identification epitope peptide of tumor antigen GPC3 and application of epitope peptide | |
| CN106117335B (en) | CTL recognition epitope peptide of tumor antigen survivin and application thereof | |
| CN105232576A (en) | DC-based therapeutic glioma vaccine and preparation method thereof | |
| CN109790224A (en) | Tumor-antigen peptide and its application derived from CACNA1H | |
| CN105219727A (en) | A kind of test kit for activating colorectal cancer specific immune response | |
| CN105219728A (en) | A kind of for activating the immunoreactive test kit of Breast Cancer-Specific | |
| CN104761636B (en) | A kind of restricted eEF2 epitope polypeptides of HLA-A33 and its application | |
| CN103911341B (en) | The preparation method of Th1 cell subsets and preparing the application in antitumor cell preparation | |
| CN110139875A (en) | Tumor-antigen peptide and its application derived from COL14A1 | |
| CN105219723A (en) | A kind of test kit for activating cancer of the stomach specific immune response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221028 Address after: No. 203, Floor 2, Medical Reproduction Center, Weiming International Health City, 511 Binhai New Avenue, Beidaihe New District, Qinhuangdao, Hebei 066600 Patentee after: Qinhuangdao Weiming Jianchangxing Medical Health Technology Co.,Ltd. Address before: Room 104, South 1st Floor, Management Committee of Chaohu Economic Development Zone, Hefei City, Anhui Province, 230000 Patentee before: ANHUI SINOBIOWAY CELL THERAPY CO.,LTD. |